BiotechTube

Micafungin + Liposomal Amphotericin B

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis

Conditions

Candidiasis

Trial Timeline

Jan 1, 2003 → Dec 1, 2005

NCT ID
NCT00106288

About Micafungin + Liposomal Amphotericin B

Micafungin + Liposomal Amphotericin B is a phase 3 stage product being developed by Astellas Pharma for Candidiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00106288. Target conditions include Candidiasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT00106288Phase 3Completed
NCT00047827Phase 2Terminated

Competing Products

20 competing products in Candidiasis

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
33
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
77
Micafungin + fluconazoleAstellas PharmaPhase 3
77
Micafungin (Mycamine)Astellas PharmaPhase 1
33
Fluconazole + MicafunginAstellas PharmaApproved
85
Micafungin + CaspofunginAstellas PharmaPhase 3
77
Micafungin + FluconazoleAstellas PharmaPhase 3
77
MicafunginAstellas PharmaPhase 2
52
micafungin + caspofunginAstellas PharmaPhase 3
77
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
77
FK463Astellas PharmaPhase 2
52
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
77
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
77
L-743,872MerckPre-clinical
23
CaspofunginMerckPhase 2
52
L-743,872MerckPhase 2
52
Caspofungin + Amphotericin B DeoxycholateMerckPhase 2
52
Caspofungin acetate + PlaceboMerckPhase 2
52
Caspofungin + Normal SalineMerckApproved
85
caspofungin acetateMerckPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85